Last updated: 2026-09-09 05:11:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Immunome, Inc. (IMNM) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $26.79, with a market capitalization of $3.04B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.67 to $30.06. This page covers its latest market performance, valuation, price trends and company information.
$3.04B | |
$26.15 | |
$63.78 | |
$2.09 | |
$26.76 | |
676.12K | |
1.34M | |
-- | |
$30.06 | |
$8.66 | |
-- | |
-- |
Immunome, Inc. (IMNM) last closed at $26.76 as of 2026-09-08 23:34:00, unchanged from the previous close of $26.76.
During the latest regular trading session, IMNM traded between $2.09 and $63.78, with a volume of 676.12K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Immunome, Inc. (IMNM) moved from $28.87 to $26.79, representing a decline of 7.19% ($2.08).
The stock traded between $25.95 and $29.11 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 822.97 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 84.7%
IMNM is currently trading at $26.79, placing it 84.7% of the way from its 52-week low of $8.67 to its 52-week high of $30.06. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 177 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Immunome, Inc. (IMNM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.